Anti-IL-23 Monoclonal Antibodies for Psoriasis

Biologics have become a well-established treatment for psoriasis, especially in those patients with moderate to severe plaque psoriasis who cannot be controlled on topical therapies. The go-to biologics were initially the tumor necrosis factor-alpha (TNF) inhibitors. Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab) and Cimzia (certolizumab pegol) are the biologics in this category. What are the… Read More

HUMIRA (adalimumab) Approved for Hidradinitis Supparitiva

Recently the biologic HUMIRA (adalimumab) was approved by the FDA for the treatment of moderate to severe hidradenitis supparativa (HS), an often debilitating disease with inflammatory papules, cysts and sinuses in the groin, axilla, inframammary and buttocks areas. This is an exciting new addition to the armamentarium of treatments, which typically include topical and oral… Read More